Welcome to our dedicated page for REPLIGEN SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REPLIGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REPLIGEN's regulatory disclosures and financial reporting.
Repligen Corporation reported strong Q2 2026 results and raised its full-year 2026 outlook while signing a definitive agreement to acquire BioLife Solutions. Q2 revenue was $204 million, up 12% as reported and 13% organic versus $182 million a year ago. GAAP income from operations was $14 million, roughly flat year-over-year, and GAAP diluted EPS was $0.09 compared with $0.26. On a non-GAAP basis, adjusted income from operations rose to $34 million from $22 million and adjusted diluted EPS increased to $0.54 from $0.37.
GAAP gross margin was 53.9% versus 51.0%, while adjusted operating margin improved to 16.7% from 12.0%, and adjusted EBITDA margin reached 21.4%. Cash, cash equivalents and marketable securities totaled $810 million at June 30, 2026. For full-year 2026, the company now guides total reported revenue to $813M–$835M (10%–13% growth; 10.5%–13.5% organic) and diluted adjusted EPS to $2.03–$2.09, with adjusted operating margin of 15.7%–16.0% and adjusted EBITDA margin of 20.6%–21.0%. Management describes the BioLife Solutions acquisition as accretive to revenue growth, margin and adjusted EPS.
Repligen Corporation agreed to acquire BioLife Solutions in a cash-and-stock transaction. Each share of BioLife common stock will be converted into the right to receive $11.25 in cash plus 0.1442 shares of Repligen common stock, subject to an adjustment cap so that total Repligen shares issued do not exceed 19.9% of Repligen’s pre-merger shares outstanding under Nasdaq rules. The deal is structured as a two-step merger, after which BioLife will become a wholly owned subsidiary of Repligen. Closing is targeted for the fourth quarter of 2026, contingent on BioLife stockholder approval, antitrust and other regulatory clearances, SEC effectiveness of a Form S-4 registration statement, Nasdaq listing of the new Repligen shares, and absence of a material adverse effect on either company. Under specified circumstances, including acceptance of a superior proposal, BioLife may owe Repligen a $59 million termination fee. The parties intend the combined mergers to qualify as a tax-free reorganization for U.S. federal income tax purposes. Repligen also furnished a press release with preliminary second-quarter 2026 results and joint communications about the transaction.
Repligen Corporation agreed to acquire BioLife Solutions in a cash-and-stock transaction valuing BioLife at $31.00 per share, or approximately $1.5 billion of enterprise value. Each BioLife share will be converted into $11.25 in cash plus 0.1442 shares of Repligen, with no fractional Repligen shares issued.
The deal, unanimously approved by both boards and expected to close in the fourth quarter of 2026, will be executed via two merger subsidiaries, making BioLife a wholly owned Repligen unit. Closing is subject to BioLife stockholder approval, antitrust clearances including the HSR Act, SEC effectiveness of a Form S-4, Nasdaq listing of new Repligen shares, and customary accuracy of representations and absence of material adverse effects. Under specified circumstances BioLife may owe Repligen a $59 million termination fee, and the merger agreement includes a no-shop with superior-proposal and fiduciary-out exceptions.
Repligen highlights the transaction as expanding its cell therapy tools portfolio and recurring consumables revenue and projects at least $20 million of year-one cost synergies, rising to $30 million in year two, with accretion of at least $0.05 to adjusted EPS in year one and $0.25 in year two. Separately, Repligen reports preliminary second-quarter 2026 revenue growth of 12% reported and 13% organic, while BioLife preliminarily reports $28.5 million in Q2 revenue, up 21% from $23.4 million.
Repligen Corp Chief Financial Officer Jason K. Garland reported selling 530 shares of Common Stock on July 16, 2026 at $150.0000 per share, in a transaction described as a sale in an open market or private transaction. The sale was effected under a Rule 10b5-1 trading plan adopted on December 8, 2025, and he now directly holds 18,829 shares.
Jason K. Garland submitted a Form 144 notice to sell up to 530 shares of common stock through Fidelity Brokerage Services LLC on 07/16/2026, with an aggregate market value of 79500.00 on NASDAQ. These shares were acquired from the issuer via Restricted Stock Vesting on 02/27/2025 as compensation. The notice also lists a prior sale on 06/25/2026 of 733 common shares for 106285.00 within the past three months.
REPLIGEN CORP CFO Jason K. Garland sold a small block of company stock in a pre-planned transaction. On the reported date, he completed an open-market sale of 733 shares of common stock at a price of $145 per share. After this sale, he directly owns 19,359 shares of Repligen common stock. The filing notes that the sale was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025, indicating the transaction was pre-scheduled rather than timed discretionarily.
Repligen Corporation director Martin D. Madaus reported equity awards, not open-market trades. He received 995 restricted stock units, each representing one share of common stock. These units vest on the earlier of May 14, 2027, one year from grant, or the next annual shareholder meeting, and settlement has been deferred until after his board service ends.
He was also granted stock options on 2,239 shares at an exercise price of $103.38 per share, vesting on the same schedule and expiring on May 14, 2036. Following these awards, he directly holds 6,581 common shares and indirectly holds additional shares through a spouse trust with 11 shares and a 2011 revocable trust with 1,800 shares.
Repligen Corporation director Konstantin Konstantinov received new equity awards consisting of restricted stock units and stock options. He was granted 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 3,889 shares after the award.
He was also granted stock options covering 2,239 shares of common stock at an exercise price of $103.38 per share, with the options expiring on May 14, 2036. Both the restricted stock units and the option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of shareholders.
Repligen Corp director Rohin Mhatre reported routine equity compensation awards. He received 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 5,014 shares after the grant.
He was also granted stock options for 2,239 shares of common stock at an exercise price of $103.38 per share. These options are exercisable starting on May 14, 2027 and expire on May 14, 2036. The restricted stock units and options each vest in full on the earlier of May 14, 2027 or the date of the next annual meeting of shareholders, which has not yet been determined.